Equities

Nanalysis Scientific Corp

Nanalysis Scientific Corp

Actions
  • Price (CAD)0.34
  • Today's Change-0.025 / -6.85%
  • Shares traded156.47k
  • 1 Year change-26.09%
  • Beta0.6757
Data delayed at least 15 minutes, as of Nov 25 2024 20:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The Company’s segments include Scientific Equipment and Security Services. Scientific Equipment segment conducts scientific equipment manufacturing and sales, primarily as a patent-protected technology Company that develops, manufactures, and sells magnetic resonance (MR) products for security, pharmaceutical, biotech, nutraceutical, chemical, food, materials, education, life science and medical applications. Security Services, focuses on providing security services, namely providing preventative and oncall maintenance services, as well as installation, of detection and analysis equipment. It offers commercial security equipment installation and maintenance services to a variety of customers in North America. It provides airport security equipment maintenance services in each province and territory of Canada.

  • Revenue in CAD (TTM)39.47m
  • Net income in CAD-12.93m
  • Incorporated2017
  • Employees130.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
VentriPoint Diagnostics Ltd.72.07k-5.02m21.80m--------302.45-0.032-0.0320.0005-0.01310.0316--0.4006---220.33-105.23-562.35-178.0148.0867.16-6,965.84-8,020.43---79.53-----27.86-3.960.0177------
Hydreight Technologies Inc13.94m-1.68m29.85m--------2.14-0.0439-0.04390.364-0.04735.3584.99227.43---64.39------40.39---12.04--0.4353------169.64--67.69------
Aurora Spine Corp23.64m-888.84k34.26m13.00--4.8560.871.45-0.0116-0.01160.30730.09071.481.894.89---5.56-16.00-8.18-22.2360.3946.65-3.76-11.761.38-2.570.4242---2.4010.83-11.93--10.36--
Conavi Medical Corp699.30k-9.70m35.42m4.00--1.82--50.64-0.9349-0.93490.01180.44030.0697----174,825.00-96.73-113.26-126.65-793.56-----1,387.40-201.89----0.3621------116.34---12.72--
Nanalysis Scientific Corp39.47m-12.93m41.30m130.00--1.59--1.05-0.1273-0.12730.38470.21370.63724.705.80303,630.80-20.87-18.30-29.36-25.3522.5842.75-32.75-39.011.03-1.540.4177--14.6927.71-63.35--15.35--
Medmira Inc383.32k-3.11m54.08m65.00------141.09-0.0045-0.00450.0006-0.0240.07520.74310.2848---61.10-69.95----62.6166.76-812.38-187.610.2112-1.96-----54.57-5.98-46.08------
Perimeter Medical Imaging AI Inc875.15k-21.68m56.05m----2.77--64.05-0.3339-0.33390.01350.20220.03142.734.98---77.72-64.55-96.20-81.4559.46---2,476.92-7,957.254.97--0.0121--203.93---41.69------
Data as of Nov 25 2024. Currency figures normalised to Nanalysis Scientific Corp's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.